Equity Details
Price & Market Data
Price: $2.40
Daily Change: +$0.09 / 3.75%
Daily Range: $2.25 - $2.53
Market Cap: $1,070,513,344
Daily Volume: 6,253,566
Performance Metrics
1 Week: 46.06%
1 Month: 40.94%
3 Months: 83.97%
6 Months: 92.80%
1 Year: 257.6%
YTD: 109.6%
About Lexicon Pharmaceuticals, Inc. (LXRX)
Get a comprehensive snapshot of Lexicon Pharmaceuticals, Inc. (LXRX). Current price: 2.40, daily change: +$0.09 / 3.75%. Market cap: 1,070,513,344. Performance YTD, 1-week, and 3-month.
Company Details
Employees: 81
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.